Hims & Hers Launches New Pill That Sends Shockwaves Across Weight-Loss Drugmakers' Stocks

Core Viewpoint - Hims & Hers Health has launched a new weight-loss pill that contains the same active ingredient as Novo Nordisk's Wegovy, leading to significant stock price movements among major weight-loss drugmakers [1] Company Impact - Shares of Eli Lilly and Novo Nordisk fell approximately 8% following the announcement of Hims & Hers' new pill, while Hims & Hers shares initially rose nearly 14% before closing down nearly 4% [1] - Hims & Hers' new pill is priced at $49 per month for five months, significantly lower than Wegovy, which costs $149 for self-pay patients [1] - Novo Nordisk has indicated plans to pursue legal action against Hims & Hers regarding the new product [1] Industry Context - The announcement comes after Eli Lilly and Novo Nordisk reported their latest earnings, with Novo Nordisk warning of potential sales declines while Eli Lilly projected continued sales growth [1] - Eli Lilly is expected to launch its own oral weight-loss medication in the second quarter of this year, pending FDA approval, which would introduce additional competition in the market [1] - Over the past 12 months, Hims & Hers shares have decreased by more than 40%, while Novo Nordisk shares have lost about 50% of their value, and Eli Lilly shares have increased by approximately 17% [1]